Start the conversation
Here at Private Briefing,we do our best to offer consistent follow-up reports on our "best idea" recommendations - including "liquid-biopsy" play TrovaGene Inc. (Nasdaq: TROV).
In the last two weeks alone we've delivered several updates on the San Diego-based firm, which we first brought your way back on March 11. And we've done at least a dozen total reports along the way.
The stock has really skidded of late - as investors have taken down an array of the stocks perceived as being among the riskiest in the market.
This is premium content for Private Briefing subscribers only.